前列腺癌根治性直线加速器立体定向放疗后的生活质量:一项纵向研究
该纵向研究纳入2016至2020年间接受前列腺癌立体定向体部放疗(SBRT)的439例患者,中位年龄73岁,中位随访34个月,采用FACT-P量表评估生活质量。结果显示FACT-P试验结果指数(p<0.0001)、FACT-General(p=0.0003)和FACT-P总分(p<0.0001)在SBRT后1个月下降,3-4个月恢复至治疗前水平;接受长期激素注射的患者(36%)首月生活质量下降尤为明显。总体而言,前列腺SBRT耐受性良好。
要点
- FACT-P相关评分在SBRT后1个月下降,3-4个月恢复至治疗前水平。
- 接受长期激素注射的患者(36%)首月生活质量下降尤为明显。
- SBRT结束1个月后,约22%的患者经历「相当程度」或更困扰的副作用。
核心结论
- 本研究展示了前列腺癌SBRT后FACT-P生活质量的纵向变化,总体上前列腺SBRT耐受性良好。
研究设计与样本
- 纵向研究,纳入2016至2020年间接受治疗的患者。
- 纳入标准为前列腺腺癌、低/中/高危风险分级、世界卫生组织体能状态0-2分。
- 共439例患者接受SBRT,中位年龄73岁,中位随访34个月。
- 生活质量采用癌症治疗功能评估-前列腺(FACT-P)量表测量。
主要发现
- FACT-P试验结果指数(p<0.0001)、FACT-General(p=0.0003)和FACT-P总分(p<0.0001)在SBRT后1个月下降,随后恢复并在SBRT后3-4个月回到治疗前水平。
- 首月生活质量下降在接受长期激素注射的患者(36%)中尤为明显。
- SBRT结束1个月后,约22%的患者经历「相当程度」或更困扰的副作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate cancer is the second most common malignancy worldwide, and the majority of patients are diagnosed with localized disease. We examined patients' quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer. METHODS: We included patients who were treated between 2016 and 2020. Inclusion criteria were adenocarcinoma of the prostate; class risk of low, intermediate, and high; and a World Health Organization performance status of 0-2. Quality of life was measured using the Functional Assessment of Cancer Therapy-Prostate (FACT-P). RESULTS: A total of 439 patients were treated with SBRT, with a median age of 73 years old. The median follow-up period was 34 months. FACT-P Trial Outcome Index (p < 0.0001), FACT-General (p = 0.0003), and FACT-P-Total (p < 0.0001) scores declined at 1 month post-SBRT, then recovered and returned to the same level as before treatment at 3-4 months post-SBRT. The decrease in quality of life in the first month was particularly remarkable in patients who received long-term hormone injections (36%). One month after the end of SBRT, about 22% of patients experienced "quite a bit" or more troubling side effects. CONCLUSIONS: This study showed longitudinal changes in quality of life by FACT-P after SBRT for prostate cancer. Overall, prostate SBRT was well tolerated.
引用
- Yamashita H, Ogita M, Sawayanagi S, et al. Quality of life after definitive linear accelerator-based stereotactic radiotherapy for prostate cancer: a longitudinal study. Radiat Oncol. 2022. PMID: 35545795. doi:10.1186/s13014-022-02061-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。